Therapies for Patients
with Significant
Unmet Need

About Us

ImmuneID is a precision therapeutics company developing transformational first-in-class and best-in-class medicines across a range of systemic autoimmune diseases, as well as cancer and neurological disorders.

Fueled by a novel, proprietary drug modality, under development in stealth mode, ImmuneID is competitively positioned to deliver life-changing therapies to patients with high unmet medical need.

Founded in late 2020 by Longwood Fund, ImmuneID is backed by top-tier biotechnology venture investors including Arch Venture Partners, Alta Partners, Pitango Healthtech Fund, Section 32, Alexandria Venture Investments, In-Q-Tel, Tekla Capital Management and Xfund.


ImmuneID is building an emerging pipeline focused on chronic diseases with enormous unmet medical need, with an initial focus on autoimmune diseases and oncology.

Join Us

We are motivated by our core values of Collaboration, Inclusion, Commitment, Integrity, and Courage. This means we put the wellbeing of our team first, and we face tough problems head-on.


View Our Open Positions

Please review our open positions, if any, and apply now. We look forward to getting to know you!

Equal Opportunity Employer

ImmuneID is proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability or any other status protected under federal, state or local law. All employment is decided on the basis of qualifications, merit and business need.